World journal of clinical oncology最新文献

{"title":"Immuno-positron emission tomography as a new frontier in imaging hematologic malignancies.","authors":"Hiroki Goto, Mariko Takano, Yoshioki Shiraishi, Sudjit Luanpitpong","doi":"10.5306/wjco.v16.i9.108585","DOIUrl":"10.5306/wjco.v16.i9.108585","url":null,"abstract":"<p><p>Immuno-positron emission tomography (immuno-PET) is an innovative medical imaging technique that combines antibodies (Abs) or other immune-targeting molecules with positron-emitting radionuclides. By targeting antigens that are highly expressed in hematologic malignancies, immuno-PET has transformed diagnostic capabilities and enables precise monitoring of therapeutic responses through highly sensitive and specific tumor cell detection. Additionally, it plays a critical role in advancing therapeutic approaches by seamlessly linking diagnostic imaging with personalized treatment strategies. Its non-invasive nature and ability to provide whole-body imaging offer significant advantages over traditional diagnostic methods, especially for detecting minimal residual disease and guiding adaptive therapeutic interventions. In Ab-based immuno-PET, positron-emitting radionuclides must have a half-life sufficient for slower pharmacokinetics and blood clearance of Abs. Recent studies have highlighted the advantages of long-lived radionuclides, such as ⁸⁹Zr, which exhibit low positron energy and enable high sensitivity and resolution, making them particularly effective for tumor visualization and characterization. This review explores the current applications, recent advancements, and potential of immuno-PET for hematologic malignancies, emphasizing its pivotal role in improving patient outcomes and advancing precision medicine.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 9","pages":"108585"},"PeriodicalIF":3.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric neuroendocrine tumors: A review of pathology and updated roadmap to surgical management.","authors":"Alexandra Z Agathis, Martina Lopez-May, Cole Brown, Celia M Divino","doi":"10.5306/wjco.v16.i9.108748","DOIUrl":"10.5306/wjco.v16.i9.108748","url":null,"abstract":"<p><p>Neuroendocrine tumors are a rare cancer, with those arising in gastric tissue even less commonly. With increasing recognition through endoscopy, these tumors are diagnosed in more patients each year. As a rare and growing entity, our understanding of these tumors, the way we characterize them, and treatment are changing rapidly. Thus, we sought to provide an updated review of pathology and management, highlighting the latest guidelines and evidence for surgical treatment. Much of the general treatment paradigm is from consensus guidelines put forth by the European Neuroendocrine Tumor Society and the North American Neuroendocrine Tumor Society; however, future research is needed to help guide further surgical decision-making around intermediate grade and intermediate size type III tumors, as well as systemic therapies in the perioperative and nonoperative settings for high-grade tumors.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 9","pages":"108748"},"PeriodicalIF":3.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic immune nutritional index-based nutritional stratification enhances recovery and survival in gastric cancer: A randomized controlled trial.","authors":"Gang Wang, Sheng-Jie Pan","doi":"10.5306/wjco.v16.i9.110068","DOIUrl":"10.5306/wjco.v16.i9.110068","url":null,"abstract":"<p><strong>Background: </strong>Postoperative malnutrition, systemic inflammation, and immune dysfunction significantly impair recovery and survival in gastric cancer patients undergoing radical gastrectomy. The Prognostic Immune Nutritional Index (PINI) enables immune-nutritional risk stratification; however, its utility in guiding perioperative nutritional support remains underexplored.</p><p><strong>Aim: </strong>To evaluate whether risk-stratified perioperative nutritional support based on PINI scores improves postoperative recovery, quality of life, and long-term outcomes in gastric cancer patients.</p><p><strong>Methods: </strong>In this prospective, randomized controlled trial, 195 patients undergoing radical gastrectomy were stratified into low- (PINI ≤ 1.5), moderate- (1.5 < PINI ≤ 3), and high-risk (PINI > 3) groups. Patients received standard, intensive, or immune-enhancing nutritional support, respectively. Outcomes were assessed at 1 week, 1 month, and 1 year postoperatively and included body mass index (BMI), serum albumin, PINI scores, Pittsburgh Sleep Quality Index (PSQI), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), Visual Analog Scale (VAS) for pain, EORTC QLQ-C30 for quality of life, complication rates, hospital stay, and survival.</p><p><strong>Results: </strong>At 1 year, the high-risk group receiving immune-enhancing nutrition demonstrated the greatest improvements, with higher serum albumin (47.5 ± 3.8 g/L) and stabilized BMI (+0.1 ± 0.2 kg/m² <i>vs</i> -0.2 ± 0.2 kg/m² in the low-risk group, <i>P</i> < 0.01). Sleep quality (ΔPSQI: -8.5 ± 2.7), anxiety (ΔSAS: -12.9 ± 3.1), and depression (ΔSDS: -12.6 ± 4.2) improved significantly (all <i>P</i> < 0.01). Pain scores were lowest (VAS: 2.1 ± 1.3), and quality of life was highest (78.2 ± 8.0, <i>P</i> < 0.01). The high-risk group also had the lowest complication rate (3.3%), shortest hospital stay (9.8 ± 2.4 days), and highest 1-year survival (98.5%, <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>PINI-based graded nutritional support significantly enhances postoperative recovery, reduces complications, and improves long-term outcomes following radical gastrectomy. These findings support its integration into precision perioperative care strategies for gastric cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 9","pages":"110068"},"PeriodicalIF":3.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MiR-451a targets mex-3 RNA binding family member C to regulate human hepatoblastoma G2 cell growth and metastasis.","authors":"De-Zheng Liu, Lin Wang, Shu-Kuan Yang, Zi-Jian Zhao, Yang-Yang Cui, Xue-Kai Zhao, Fan Zhang, Qing-Hai Guan, Lei Zhou","doi":"10.5306/wjco.v16.i9.111742","DOIUrl":"10.5306/wjco.v16.i9.111742","url":null,"abstract":"<p><strong>Background: </strong>Aberrant microRNAs expression and associated pathways have been proved participate in regulation vast various physiologic and pathologic processed of different human cancers including liver cancer. While, the function of miR-451a in liver cancer still indistinct.</p><p><strong>Aim: </strong>To study the effect of miR-451a in liver cancer development.</p><p><strong>Methods: </strong>GeneChip microarray analysis performed to detect miR-451a expression in liver cancer tissues and normal liver tissues. Reverse transcription-polymerase chain reaction was used to validate the expression of miR-451a in liver cancer cell and other tumor cell lines. Construction of liver cancer cell lines that stably overexpressed miR-451a by transfecting Lentivirus produced by Genechem company. Methylthiazolyldiphenyl-tetrazolium (MTT) bromide assay and colony formation assay to determine the effect of miR-451a in liver cancer cell proliferation. Flow cytometry used to investigate whether miR-451a involved in liver cancer cell apoptosis. Cell migration ability was measured <i>via</i> wound scratch assay. Target gene was explored by bioinformatic analysis, and downstream molecule of miR-451a in liver cancer identified by rescue experiments.</p><p><strong>Results: </strong>MiR-451a expression significantly downregulation in liver cancer tissues compared with that in normal liver tissue. MiR-451a also obviously low-expressed in liver cancer cell, colorectal carcinoma cell and esophageal carcinoma cell lines. Human hepatoblastoma G2 (HepG2) and BEL-7404 cell lines that stably overexpressed miR-451a by transfecting lentivirus constructed successfully. MTT bromide assay and colony formation assay showed that the overexpressed miR-451a inhibit HepG2 cell proliferation viability, but not BEL-7404 cell. Flow cytometry determined that miR-451a regulating proliferation not through inducing apoptosis. Wound scratch assay revealed that miR-451a overexpression suppressed HepG2 cell migration. Furthermore, mex-3 RNA binding family member C was predicted as the target gene by bioinformatic analysis, and rescue experiments confirmed the hypothesis.</p><p><strong>Conclusion: </strong>Therefore, miR-451a may be candidate miRNA for understanding molecular mechanisms of liver cancer development and novel target in liver cancer cell.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 9","pages":"111742"},"PeriodicalIF":3.2,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145192885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive surgery for colorectal cancer emergencies.","authors":"Neng-Wei Wong, Salman Ahmed Abdul Jabbar, James Chi-Yong Ngu, Nan-Zun Teo","doi":"10.5306/wjco.v16.i8.107757","DOIUrl":"10.5306/wjco.v16.i8.107757","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality globally, and its management in the emergency setting presents distinct challenges. In addition to its advantages in elective CRC surgery, studies have demonstrated that minimally invasive surgery (MIS) can provide benefits in CRC emergencies, such as reduced morbidity and a shorter length of hospitalization. However, the applicability of MIS in the emergency setting is limited by factors such as compromised patient physiology, resource constraints, and the need for technical expertise. As an alternative to emergency MIS, endoscopic interventions have also been increasingly supported by emerging evidence as a bridge to surgery. This article appraises contemporary guidelines and the evidence behind their recommendations for MIS surgery in CRC emergencies, whilst highlighting the challenges to implementation and the strategies to overcome them.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107757"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deciphering prognostic markers in gastric signet ring cell carcinoma: Human epidermal growth factor receptor 2 and other key factors.","authors":"Noura Atef A Ebrahim, Moamen O Othman, Neveen S Tahoun, Rasha A Salama, Aya Arafat, Nancy H Amin","doi":"10.5306/wjco.v16.i8.107987","DOIUrl":"10.5306/wjco.v16.i8.107987","url":null,"abstract":"<p><strong>Background: </strong>Gastric signet ring cell carcinoma (SRCC) is a rare, aggressive subtype of gastric cancer characterized by poor prognosis and distinctive biological behavior. Despite advances in gastric cancer treatment, SRCC remains difficult to diagnose early and manage effectively due to its infiltrative pattern and molecular variability. Reliable prognostic markers are critical to guide clinical management.</p><p><strong>Aim: </strong>To investigate the prognostic factors, including human epidermal growth factor receptor 2 (HER2) expression, associated with survival outcomes in patients with gastric SRCC.</p><p><strong>Methods: </strong>A retrospective analysis of 100 cases diagnosed between 2015 and 2019 was conducted, assessing demographic, clinical, and pathological data. HER2 expression was analyzed using immunohistochemistry, and survival outcomes, including overall survival and disease-free survival, were examined.</p><p><strong>Results: </strong>With a median follow-up of 43 months, the median patient age was 50 years, and males exhibited a higher mortality rate (<i>P</i> = 0.0107). Elevated serum carbohydrate antigen 19-9 and carcinoembryonic antigen levels were significantly associated with increased mortality (<i>P</i> = 0.00149 and <i>P</i> = 0.00163, respectively). Advanced tumor-node-metastasis stage and lymphovascular invasion were strong predictors of poor outcomes (<i>P</i> < 0.001 and <i>P</i> = 0.019). HER2 positivity correlated with higher mortality (<i>P</i> = 0.00882) but was not significantly linked to recurrence (<i>P</i> = 0.53). Surgical treatment significantly improved survival compared with non-surgical approaches (<i>P</i> = 0.0226).</p><p><strong>Conclusion: </strong>These findings highlight the aggressive nature of SRCC with advanced disease stage, elevated tumor markers, and lymphovascular invasion contributing to poor outcomes. HER2 expression, though infrequent, may indicate worse prognosis, reinforcing the role of surgical intervention in survival improvement.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107987"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucose and antidiabetic therapy in temozolomide resistance in glioblastoma.","authors":"Emir Begagić, Amina Džidić-Krivić, Hakija Bečulić, Ragib Pugonja, Adnana Ljevaković, Binasa Bašić, Adem Nuhović, Elma Milanović, Semir Hadžić, Emir Bećirović, Lemana Buljubašić, Minela Bećirović, Mirza Pojskić","doi":"10.5306/wjco.v16.i8.108112","DOIUrl":"10.5306/wjco.v16.i8.108112","url":null,"abstract":"<p><p>Glioblastoma (GBM) remains a major clinical challenge due to limited therapeutic success despite standard treatments including surgery, radiotherapy, and temozolomide (TMZ). Recent evidence links hyperglycemia to cancer progression, and altered glucose metabolism has emerged as a key factor in GBM development. Metformin, an antidiabetic drug, has shown promise in improving survival in GBM patients, possibly due to its ability to cross the blood-brain barrier and target metabolic pathways involved in tumor growth. Preclinical studies suggest metformin may enhance TMZ efficacy by acting on glioma stem cells and overcoming resistance mechanisms. Its activation of AMPK and modulation of Wnt signaling further support its therapeutic potential. However, while early studies and clinical trials have explored metformin's safety and efficacy, its direct impact on GBM survival remains unclear. Ongoing research aims to clarify its mechanisms and identify responsive patient subgroups. Novel strategies, including PPARγ agonists and nanoerythrosome-based drug delivery systems, are also under investigation to improve metformin's therapeutic profile. Rigorous clinical trials and mechanistic studies are essential to determine the role of metformin as adjunct therapy in GBM treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"108112"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of physical activity in cancer prevention: An update.","authors":"Deepak Dhamnetiya, Aishwarya Sharma","doi":"10.5306/wjco.v16.i8.107765","DOIUrl":"10.5306/wjco.v16.i8.107765","url":null,"abstract":"<p><p>Cancer prevention <i>via</i> regular physical activity has been studied across the world. This minireview aimed to present the latest updates in research in the context of the role of physical activity in the cancer prevention. The various mechanisms at the molecular level were studied in depth. The essential processes at play involving hormonal balance, weight reduction, adiposity, inflammation, immunity, sunlight exposure and vitamin D levels and insulin resistance were critically analyzed here. The dose response of exercise with respect to cancer prevention was appraised. Strong evidence supports an inverse relationship between physical activity and cancer risk, particularly for breast, liver, lung and colorectal cancers. There is limited evidence for hematologic, head and neck, ovarian, pancreas, prostate, brain, thyroid and rectal cancer. Prehabilitation plays a key role in tertiary prevention of cancer and patient symptom alleviation. The role of physical activity was studied under the entire cancer continuum, from primary to tertiary prevention. The minireview highlights the need for interventional trials involving holistic methods combing modern and traditional medicine/therapies in cancer prevention.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107765"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases.","authors":"Xue-Jie Liu, Heng Ge, Chun-Luan Yuan","doi":"10.5306/wjco.v16.i8.107009","DOIUrl":"10.5306/wjco.v16.i8.107009","url":null,"abstract":"<p><strong>Background: </strong>The optimal sequencing of immune checkpoint inhibitor (ICI) and brain radiotherapy in the management of brain metastasis from non-small cell lung cancer (NSCLC) is unclear.</p><p><strong>Aim: </strong>To evaluate the survival of concurrent ICI and consolidation ICI in NSCLC patients treated with brain radiotherapy.</p><p><strong>Methods: </strong>We retrospectively analyzed NSCLC patients treated with brain radiotherapy and ICI. Treatment response and survival were estimated. The cox proportional hazards regression model was utilized to investigate the association between overall survival and clinical variables.</p><p><strong>Results: </strong>There were 54 patients in concurrent ICI and radiotherapy group, and 62 individuals treated with radiotherapy followed by consolidation ICI. The objective response rates were similar between the two group. The median progression free survival was significantly high in the concurrent ICI group compared with consolidation ICI group (9.56 months <i>vs</i> 8.15 months, <i>P</i> = 0.038). In addition, the median overall survival was 22.08 months in the concurrent ICI group, clearly longer than that in the consolidation group (13.24 months, <i>P</i> = 0.009).</p><p><strong>Conclusion: </strong>In NSCLC patients with brain metastases, our analyses suggested that radiotherapy concurrent with ICI was associated with significant benefit compared with radiotherapy followed by consolidation ICI.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"107009"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination therapy reduces transarterial chemoembolization resistance in advanced hepatocellular carcinoma.","authors":"Hu-Yu Jiao, Xin-Mei Yan, Jun-Xin Li, Zhen-Gang Zhang","doi":"10.5306/wjco.v16.i8.109419","DOIUrl":"10.5306/wjco.v16.i8.109419","url":null,"abstract":"<p><strong>Background: </strong>Transarterial chemoembolization (TACE) is a main treatment for advanced hepatocellular carcinoma (HCC), but tumors often become resistant. Combining TACE programmed cell death (ligand) 1 [PD-(L)1] inhibitors and molecular targeted therapies (MTT) may improve outcomes, but its role in preventing TACE resistance requires further investigation.</p><p><strong>Aim: </strong>To compare if TACE plus PD-(L)1 inhibitors and MTT reduces TACE resistance and improves survival in advanced HCC compared to TACE alone.</p><p><strong>Methods: </strong>We analyzed 721 patients: 532 received TACE only, and 72 received TACE with PD-(L)1 inhibitors and MTT. After matching patient characteristics, 144 patients (72 pairs) were compared. Tumor progression after 3 treatment cycles was measured.</p><p><strong>Results: </strong>The combination group exhibited significantly lower TACE resistance rates compared to the monotherapy group (9.7% <i>vs</i> 38.8%, <i>P</i> < 0.001). Moreover, patients in the combination group experienced prolonged progression-free survival (progression-free survival: 17.5 months <i>vs</i> 9.1 months, <i>P</i> = 0.004) and overall survival (overall survival: 20.8 months <i>vs</i> 16.4 months, <i>P</i> = 0.008). These findings underscore the efficacy of combination therapy in enhancing therapeutic outcomes in advanced HCC.</p><p><strong>Conclusion: </strong>Adding immunotherapy and targeted drugs to TACE significantly reduces treatment resistance and improves survival in advanced liver cancer, suggesting it may become a new standard treatment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 8","pages":"109419"},"PeriodicalIF":3.2,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144993608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}